Astellas Pharma (OTCMKTS:ALPMY) Downgraded to “Hold” Rating by Zacks Research

Astellas Pharma (OTCMKTS:ALPMY) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

Separately, Jefferies Financial Group upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Astellas Pharma presently has an average rating of “Hold”.

Astellas Pharma Stock Down 1.5%

Shares of ALPMY opened at $13.09 on Wednesday. The company has a market capitalization of $23.69 billion, a P/E ratio of 12.19 and a beta of 0.07. Astellas Pharma has a one year low of $9.91 and a one year high of $17.35. The business’s 50 day simple moving average is $13.51 and its 200-day simple moving average is $14.64. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.17 and a quick ratio of 0.90.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings data on Monday, April 27th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.14. The firm had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.28 billion. Astellas Pharma had a return on equity of 23.54% and a net margin of 13.66%. As a group, sell-side analysts predict that Astellas Pharma will post 1.25 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).